Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 13/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21625512 | 0.75 | NOS3 (0.35) | NOS3NOS2P2RX3P2RX2 | |
| SCHEMBL28527776 | 0.73 | NOS3 (0.31) | NOS3NOS2 | |
| SCHEMBL20698992 | 0.73 | P2RX3 (0.31) | NOS3NOS2P2RX3P2RX2 | |
| SCHEMBL23234577 | 0.73 | GABRA1 (0.33) | NOS3NOS2P2RX3P2RX2 | |
| SCHEMBL9777725 | 0.73 | LMNA (0.41) | NOS3NOS2P2RX3P2RX2 | |
| SCHEMBL21637156 | 0.70 | NOS3 (0.40) | NOS3NOS2P2RX3P2RX2 | |
| SCHEMBL21625501 | 0.70 | NPC1 (0.38) | P2RX3P2RX2 | |
| SCHEMBL22014867 | 0.70 | TDP1 (0.33) | NOS3NOS2 | |
| SCHEMBL30148011 | 0.70 | NUDT1 (0.37) | NUDT1 | |
| SCHEMBL28539175 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | NUDT1 1805/4885NOS3 2127/4885NOS2 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.